Cargando…
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Most patients with metastatic breast cancer or gastric cancer who are treated with trastuzumab, an anti-HER2 monoclonal antibody, become refractory to the drug within a year after the initiation of treatment. Although the combination of trastuzumab with pertuzumab produced synergetic effects in the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
De Gruyter
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835198/ https://www.ncbi.nlm.nih.gov/pubmed/36694697 http://dx.doi.org/10.1515/biol-2022-0535 |